Cargando…

Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL

The Japan Adult Leukemia Study Group (JALSG) Ph+ALL202 study reported a high complete remission (CR) rate for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients treated with imatinib-combined chemotherapy. However, the long-term treatment efficacy remains uncertain. Here...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hatta, Yoshihiro, Mizuta, Shuichi, Matsuo, Keitaro, Ohtake, Shigeki, Iwanaga, Masako, Sugiura, Isamu, Doki, Noriko, Kanamori, Heiwa, Ueda, Yasunori, Yoshida, Chikamasa, Dobashi, Nobuaki, Maeda, Tomoya, Yujiri, Toshiaki, Monma, Fumihiko, Ito, Yoshikazu, Hayakawa, Fumihiko, Takeuchi, Jin, Kiyoi, Hitoshi, Miyazaki, Yasushi, Naoe, Tomoki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097750/ https://www.ncbi.nlm.nih.gov/pubmed/29694642 http://dx.doi.org/10.1007/s00277-018-3323-8

Ejemplares similares

High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT Study
por: Nishiwaki, Satoshi, et al.
Publicado: (2023)

Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3‐internal tandem duplication AML: The JALSG AML209‐FLT3‐SCT study
por: Kawashima, Naomi, et al.
Publicado: (2020)

Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL
por: Mizuta, S, et al.
Publicado: (2012)

1018. Prevalence of Bacteremia/Fungemia and Pneumonia in Remission Induction Chemotherapy for Adult Acute Myeloid Leukemia From 1987 to 2005: Japan Adult Leukemia Study Group (JALSG)
por: Kato, Hideaki, et al.
Publicado: (2018)

Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature
por: Takeshita, Akihiro, et al.
Publicado: (2020)

The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib
por: Morishita, Takanobu, et al.
Publicado: (2016)

Modern Management Options for Ph+ ALL
por: Ribera, Josep-Maria, et al.
Publicado: (2022)

Blinatumomab in Ph+ B-ALL: present and perspectives
por: Papayannidis, Cristina, et al.
Publicado: (2017)

Request for All - Generalized Request Framework for PhEDEx
por: Huang, C-H, et al.
Publicado: (2013)

Resistant mutations in CML and Ph(+)ALL – role of ponatinib
por: Miller, Geoffrey D, et al.
Publicado: (2014)

Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts
por: Ono, Takaaki, et al.
Publicado: (2014)

Request for All - A Generalized Request Framework for PhEDEx
por: Huang, C -H, et al.
Publicado: (2014)

Chondrocytes, synoviocytes and dermal fibroblasts all express PH-20, a hyaluronidase active at neutral pH
por: El Hajjaji, Hafida, et al.
Publicado: (2005)

pH effect on strain-specific transcriptomes of the take-all fungus
por: Gazengel, Kévin, et al.
Publicado: (2020)

Basic and clinical study of efficacy and adverse effects of flumatinib in Ph(+) ALL
por: Wang, Jun, et al.
Publicado: (2023)

BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells
por: Inoue, Chisato, et al.
Publicado: (2018)

High Incidence of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (Ph-like ALL) in Older Adults with B-ALL
por: Tasian, Sarah K, et al.
Publicado: (2016)

Quantum chemical calculations on a unified pH scale for all phases
por: Goll, SK, et al.
Publicado: (2011)

APOLs with low pH dependence can kill all African trypanosomes
por: Fontaine, Frédéric, et al.
Publicado: (2017)

Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL
por: Wieduwilt, Matthew J., et al.
Publicado: (2021)

Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib
por: Bardy-Bouxin, Nathalie, et al.
Publicado: (2015)

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL
por: Aldoss, Ibrahim, et al.
Publicado: (2022)

The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells
por: Kuwatsuka, Y, et al.
Publicado: (2011)

PH WINS for All: The Critical Role of Partnerships for Engaging All Local Health Departments in the Public Health Workforce Interests and Needs Survey
por: Kulik, Phoebe K. G., et al.
Publicado: (2023)

mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL
por: Gotesman, Moran, et al.
Publicado: (2018)

C(60) Bioconjugation with Proteins: Towards a Palette of Carriers for All pH Ranges
por: Di Giosia, Matteo, et al.
Publicado: (2018)

Philadelphia-positive (PH+) acute lymphoblastic leukemia (ALL): developing strategies for curing this stubborn disease
por: Liam, Christopher Chin Keong, et al.
Publicado: (2022)

Unusual PDGFRB fusion reveals novel mechanism of kinase activation in Ph-like B-ALL
por: Sadras, Teresa, et al.
Publicado: (2023)

PB1710: AN EXTENDED FLOW CYTOMETRY PANEL AS A SCREENING TOOL FOR PH-LIKE ALL
por: Cieloch, Adrianna, et al.
Publicado: (2023)

P372: CMV REACTIVATIONS/INFECTIONS IN PH+ ALL PATIENTS TREATED WITH DASATINIB WITH OR WITHOUT BLINATUMOMAB. A RETROSPECTIVE MULTICENTER CAMPUS ALL STUDY
por: Annunziata, Mario, et al.
Publicado: (2023)

CML Developing Three Years after Therapy Completion in a Child with Ph(−) Pre-B-ALL
por: Hosseini, S., et al.
Publicado: (2011)

A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL
por: Rix, Uwe, et al.
Publicado: (2013)

BCR‐ABL enhances the prolyl isomerase activity of Pin 1 by interacting with DAPK1 in ph(+) ALL
por: Cao, Wen‐bin, et al.
Publicado: (2018)

T315I clone selection in a Ph+ all patient under low‐dose ponatinib maintenance
por: Noetzli, Jasmine, et al.
Publicado: (2017)

Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL
por: Short, Nicholas J., et al.
Publicado: (2020)

Identification of immune subtypes of Ph-neg B-ALL with ferroptosis related genes and the potential implementation of Sorafenib
por: Hong, Yang, et al.
Publicado: (2021)

G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL
por: Iacobucci, Ilaria, et al.
Publicado: (2022)

CAR-T cell therapy followed by allogenic hematopoietic stem cell transplantation yielded comparable outcome between Ph like ALL and other high-risk ALL
por: Dai, Hai-ping, et al.
Publicado: (2023)

P396: FIFTEEN YEARS OF RUSSIAN RESEARCH IN THE TREATMENT OF ADULT PATIENTS WITH ACUTE PH-NEGATIVE LYMPHOBLASTIC LEUKEMIA ACCORDING TO THE PROTOCOLS ALL-2009 AND ALL-2016.
por: Aleshina (Gavrilina), Olga, et al.
Publicado: (2023)

Dasatinib-based 2-step induction for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
por: Sugiura, Isamu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_181la2s2n2lolp3cr10lvd3145